This article examines viral and non-viral vectors in gene therapy, highlighting their mechanisms, advantages, and limitations ...
PARIS, France I February 12, 2025 I GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and ...